Enhanced production of shikimic acid using a multi-gene co-expression system in Escherichia coli.
10.1016/S1875-5364(16)30029-2
- Author:
Xiang-Lei LIU
1
;
Jun LIN
2
;
Hai-Feng HU
1
;
Bin ZHOU
1
;
Bao-Quan ZHU
3
Author Information
1. State Key Laboratory of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai 201203, China.
2. State Key Laboratory of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai 201203, China. Electronic address: junlin621@126.com.
3. State Key Laboratory of New Drug and Pharmaceutical Process, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai 201203, China. Electronic address: baoquanzhu@126.com.
- Publication Type:Journal Article
- Keywords:
Escherichia coli;
Multi-gene co-expression;
Shikimic acid
- MeSH:
Escherichia coli;
enzymology;
genetics;
metabolism;
Escherichia coli Proteins;
genetics;
metabolism;
Plasmids;
genetics;
metabolism;
Shikimic Acid;
metabolism
- From:
Chinese Journal of Natural Medicines (English Ed.)
2016;14(4):286-293
- CountryChina
- Language:English
-
Abstract:
Shikimic acid (SA) is the key synthetic material for the chemical synthesis of Oseltamivir, which is prescribed as the front-line treatment for serious cases of influenza. Multi-gene expression vector can be used for expressing the plurality of the genes in one plasmid, so it is widely applied to increase the yield of metabolites. In the present study, on the basis of a shikimate kinase genetic defect strain Escherichia coli BL21 (ΔaroL/aroK, DE3), the key enzyme genes aroG, aroB, tktA and aroE of SA pathway were co-expressed and compared systematically by constructing a series of multi-gene expression vectors. The results showed that different gene co-expression combinations (two, three or four genes) or gene orders had different effects on the production of SA. SA production of the recombinant BL21-GBAE reached to 886.38 mg·L(-1), which was 17-fold (P < 0.05) of the parent strain BL21 (ΔaroL/aroK, DE3).
